A Personalised Clinical Dynamic Prediction Model to Characterise Prognosis for Patients with Localised Prostate Cancer: analysis of the CHHiP Phase III Trial redjournal.org/article/S0360-…
English
Mark Brook
35 posts
Mark Brook
@MarkNBrook
Biostatistician in The Division of Genetics and Epidemiology at @ICR_London ORCID: https://t.co/Uji4eswv8s
Katılım Ocak 2021
140 Takip Edilen47 Takipçiler
Mark Brook retweetledi
Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study
buff.ly/3jcAERZ
@HolsUroLols @zx8754 @kotezsofi
English
Mark Brook retweetledi
Excited to see this work published! In a large sample of >22K African ancestry men, we show that a rare #HOXB13 variant found only in men of West African ancestry is associated with 2.4-fold higher risk of overall #prostatecancer and 5.1-fold higher risk of metastatic disease.
European Urology@EUplatinum
A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry buff.ly/3I2YyGw @BurcuDarst et al. "HOXB13 X285K was associated with 2.4-fold increased odds of PCa (95% CI 1.5-3.9), with greater risk for more aggressive/advanced disease"
English
"Risk of breast cancer in men in relation to weight change: a national case-control study in England and Wales"
Anthony Swerdlow, @CydneyLBruce, Rosie Cooke, Penny Coulson, @Minouk_Schoe, Michael Jones @AlchemiJones in IJC @intjcanc
onlinelibrary.wiley.com/doi/10.1002/ij…
English
Mark Brook retweetledi
Very sad that Hon Fellow of @BritishAcademy_ Sir David Cox has died. He was a towering figure in the field of statistics. I remember getting him to do one of the @RoyalStatSoc 180th anniversary lectures in 2014 when he was 90 and still on fine form youtu.be/xRik3vOKLcU
YouTube
English
Mark Brook retweetledi
Our manuscript on the evaluation of associations of BRCA1 and BRCA2 mutations with 22 different cancers (other than breast/ovarian cancers in women) out @JCO_ASCO. Analysed Data from >5000 families with mutations from CIMBA
@oncoalert #gcchat @CRUK_CI
ascopubs.org/doi/abs/10.120…
English
Mark Brook retweetledi
Results of the first screening round of the IMPACT study for men with mismatch repair genes pathogenic variants.
Read more 👇
prostate.uroonco.uroweb.org/publication/pr…
#prostatecancer #Movember
@marcobrooko @judeoffman @SapnaSyngal @roodvdb
English
"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study"
Elizabeth Bancroft @LizBancroft2, Elizabeth Page, Ros Eeles in @TheLancetOncol
thelancet.com/journals/lanon…
English
Mark Brook retweetledi
"Our new findings show that PSA testing in men with #LynchSyndrome is much more likely to pick up life-threatening #ProstateCancer than in the general population." - Professor Rosalind Eeles, of the ICR and @royalmarsdenNHS.
Read more in @BBCNews.
bbc.co.uk/news/health-58…
English
Mark Brook retweetledi
The PROFILE study aims to understand why some men, including black men, are at greater risk of #ProstateCancer.
Winston, Richard, Frederick, and Olivier explain why more men should sign up 👇🏿👇🏼👇🏾
#BlackInCancerWeek21 @cancerBRC @royalmarsdenNHS @ProstateUK @realpaulparker2
English
@mitchiela @paulpharoah @siddhartha_kar Yes! I use this all the time when compliling large author lists. Really useful.
English
@paulpharoah @siddhartha_kar Glad you discovered AuthorArranger! Please share widely to others who might find it useful. Saves me tons of time...but I am biased.
authorarranger.nci.nih.gov/#/
English
I've just discovered AuthorArranger (thx @siddhartha_kar ). Looks very useful.
English
Mark Brook retweetledi
📢 The ICR's and @royalmarsdenNHS' PACE-B trial showed that using advanced radiotherapy called SBRT to deliver precise treatment over a short time frame in #ProstateCancer, didn't lead to worse side effects compared to standard #Radiotherapy 👇
icr.ac.uk/news-archive/s…
English
Mark Brook retweetledi
An interesting tale of science communication, journalism and the culture wars has just dropped - 🧵
@JenniferRaff @ewanbirney @aylwyn_scally @minouye271 + I recently published a paper about the lexicon of genetics, and how it needs to be addressed
bit.ly/3ddQu96
English
Mark Brook retweetledi
"Thanks to you, this study will help us understand more about the genetics of prostate cancer."
@realpaulparker2 is taking part in our groundbreaking PROFILE study to help us understand why black men are twice as likely to get prostate cancer.
Join him: bit.ly/2I4rJzt
English
Mark Brook retweetledi
A group of us (@minouye271, @JenniferRaff, @aylwyn_scally @AdamRutherford and myself) have written a piece on the language we use in genetics; untangling from previous sometimes racist language and being more precise and less harmful. We welcome feedback. arxiv.org/abs/2106.10041
English
Mark Brook retweetledi
Constructing and evaluating risk models in non-European ancestry populations is essential to broaden the impact of genomic medicine. Excited to be a part of this group @ChrisHaiman @johnwitte @GENES_PK and others supported by the consortium. @KECKSchool_USC @uscphs @USCBiostat
National Human Genome Research Institute@genome_gov
Research studies are starting to use polygenic risk scores to determine a person’s inherited risk for diseases. @NIH is awarding grants to develop methods that will improve how polygenic risk scores can be used to predict disease in diverse communities. bit.ly/3wednRj
English
Mark Brook retweetledi
Looking forward to Stephen Chanock talking on “Radiation, genomic alterations in papillary thyroid carcinoma and transgenerational studies following the Chernobyl accident” @mrc_ieu online seminar 21st June 3pm UK time, all welcome bristol.ac.uk/integrative-ep…
English
Mark Brook retweetledi
so excited to see this out. TWAS fails to implicate many risk regions as it focuses on steady-state expression levels. Enter CWAS, that uses chromatin variation to reveal context-dependent gene regulation as drivers of prostate cancer risk
biorxiv.org/content/10.110…
English
Mark Brook retweetledi
Really nice editorial on our recent @EUplatinum publication describing the combined effect of rare and common variants in #ProstateCancer. Discusses the use of RPMs/PRS/fam hx for screening and next steps needed to evaluate the clinical utility of #PRS
europeanurology.com/article/S0302-…
English